CureVac reports further data on COVID-19 vaccine candidate

• CureVac (NASDAQ:CVAC) perks 8% premarket in reaction to publication of detailed interim Phase 1 data, following the positive topline data reported on November 2.
• The previous interim data showed that CVnCoV was generally well tolerated across all tested doses (2-12µg) and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation.
• The interim analysis shows that two doses of CVnCoV, administered 28 days apart were safe.
• No vaccine-related serious adverse events were reported.
• There were dose-dependent increases in frequency and severity of solicited systemic adverse events.
• Median titers measured in these assays two weeks after the second 12 μg dose were comparable to the median titers observed in convalescent sera from COVID-19 patients.
• Seroconversion of virus neutralizing antibodies occurred in all participants who received 12 μg doses.
• CVnCoV is safe and well tolerated and is able to boost the pre-existing immune response even at low dose levels.
• Based on these results, the 12 μg dose is selected for further clinical investigation, including a phase 2b/3 study which is expected to initiate by the end of 2020.
• The manuscript is available on medRxiv and will also be submitted for publication in a peer-reviewed journal.
• CureVac will host a conference call and webcast today at 5 p.m. CET (11 a.m. EST) to provide more insight on the interim data.
• https://seekingalpha.com/news/3634353-curevac-reports-data-on-covidminus-19-vaccine-candidate-cvncov